Clinical Trial Update: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating gemcitabine/cisplatin/nab-paclitaxel with rilvegostomig in resectable cholangiocarcinoma; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Cholangiocarcinoma Resectable | Phase 2 | Status: NOT_YET_RECRUITING